Expert Interview
A Second View: Examining IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial
Ticker(s): IMUXInstitution: Mayo Clinic
- Professor of Medicine at the Mayo Clinic in Rochester Minnesota.
- Expert in IBD, which is also the focus of her research work encompassing new therapies, gender-specific issues and medical adherence.
- Published over 200 original articles, reviews and book chapters along with two first editions of a book for patients on self-management of IBD.
Roughly how many patients with UC do you currently manage?
Added By: c_adminWhat are your thoughts on the potential of DHODH inhibition in UC?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement forIMU-838?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
